Bristol-Myers Squibb Company
345 Park Avenue
About Bristol-Myers Squibb Company
Network with Bristol-Myers Squibb representatives at the Spring 2018 Biotech Bay Talent Connect! Click here for more information
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
Founder: Edward Robinson Squibb
CEO: Giovanni Caforio, MD
CFO: Charles Bancroft
Please click here for clinical trial information.
Please click here for Bristol-Myers Squibb job opportunities.
Please click here to see all products.
For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.
FOLLOW BRISTOL-MYERS SQUIBB:
Tweets by Bristol-Myers Squibb
1794 articles with Bristol-Myers Squibb Company
Novartis announced that John Tsai, formerly of Amgen, is joining the company as Head of Global Drug Development and chief medical officer.
Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
Bristol-Myers Squibb announced initial positive Phase III data, yet company shares dropped more than six percent.
4/13/2018There has been speculation for several years whether Pfizer Inc. would consider buying Bristol-Myers Squibb. That appears to have been laid to rest by comments made by Pfizer’s chief executive officer, Ian Read.
Bristol-Myers Squibb and the Harvard Fibrosis Network, part of the Harvard Stem Cell Institute, have launched a collaboration to discover and develop new therapies for fibrotic diseases.
The Harvard Fibrosis Network brings together researchers across the schools and affiliated hospitals of Harvard University.
The relationship between pharmaceutical companies and patient advocacy groups is long and deep and involves millions of dollars in donations, a new report reveals.
Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.
Shares of Incyte Corporation are down more than 20 percent this morning after the company revealed that pairing is IDO1 drug in combination with Merck’s Keytruda failed to meet endpoints in a Phase III melanoma trial.
Eli Lilly and Company announced top-line data from its Phase III REACH-2 trial of Cyramza (ramucirumab) as a monotherapy second-line treatment for hepatocellular carcinoma (HCC), which is liver cancer.
Bristol-Myers Squibb Company will hold an investor event on Monday, April 16, 2018 at 6:00 p.m. EDT (5:00 p.m. CDT) to discuss data presented at the Annual Meeting of the American Association for Cancer Research (AACR) in Chicago.
The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients.This marks the third HIV approval for the company.
Versant Ventures spinoff company Tempest Therapeutics secured $70 million in a Series B funding to advance the company’s immunotherapy pipeline.
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for Previously Treated Patients with MSI-H or dMMR Metastatic Colorectal Cancer for Priority Review
The FDA also granted the Opdivo plus Yervoy combination Breakthrough Therapy Designation for this potential indication.
The U.S. Food and Drug Administration (FDA) accepted Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) with Yervoy (ipilimumab) for a type of colorectal cancer.
Genentech's Late-Stage Trial Data Shows Combination of Tecentriq and Avastin Helps NSCLC Patients...
3/26/2018Genentech is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of an every four-week (Q4W) Opdivo (nivolumab) dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced melanoma and previously treated renal cell carcinoma.
Seattle Genetics announced today that the FDA has granted approval for its Adcetris drug to treat Hodgkins Lymphoma.
Tecentriq's Phase III results gives Genentech a lead for potentially becoming the first-line treatment for squamous non-small cell lung cancer.